KV Pharmaceutical - Media Contacts


	About Us Corporate Officers Board of Directors Community Citizenship Our Brands Makena^® (hydroxyprogesterone caproate injection) Evamist^® (estradiol transdermal spray) Clindesse^® (clindamycin phosphate) Gynazole-1^® (Butoconazole Nitrate Vaginal Cream USP, 2%) Ask the Healthcare Professional Investor Relations SEC Filings News » Recent Headlines Press Releases Conference Calls Media Contacts Upcoming Investor Events Investor FAQs Investor Contacts Corporate Governance Corporate Officers Board of Directors Research & Development Update on Ongoing Makena^® (hydroxyprogesterone caproate injection) Research

5/21/2013 12:37:04 PM

KVPHQ:

KVPBQ:


	Media Contacts

For media related information and inquiries please contact:

Investor Relations Department
KV Pharmaceutical Company
2280 Schuetz Road
St. Louis, MO 63146
Phone: 314-645-6600, Ext. 3307
Fax: 314-646-3705

Investor Relations Contact:
Brad Edwards
Brainerd Communicators
Phone: 212-986-6667

Investor E-mail Inquiries:
investorrelations@kvpharmaceutical.com

Home | Contact Us | Site Directory | Legal/Privacy | Compliance Program